|Bid||3.70 x 3100|
|Ask||5.92 x 1800|
|Day's Range||3.91 - 4.07|
|52 Week Range||3.31 - 15.00|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
-- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial.
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant gram-negative ...
--Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT--. SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing ...
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018-- Achaogen, Inc., a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today highlighted ...
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northeast ...
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference taking place August 14 to 15, 2018 in New York City. Achaogen management will present at 8:00 a.m. Eastern Time on Tuesday, August 14th, 2018. A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com.
--ZEMDRI, approved in the U.S. for the treatment of adults with complicated urinary tract infections--. --Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ZEMDRI when administered in the hospital inpatient setting. In the final rule concerning Hospital Inpatient Prospective Payment Systems and Fiscal Year 2019 Rates, CMS stated that “ZEMDRI offers a substantial clinical improvement for patients who have limited or no alternative treatment options because it is a new antibiotic that offers a treatment option for a patient population unresponsive to currently available treatments” and that “ZEMDRI meets all the criteria for approval of new technology add-on payments.” Additional information on the final rule and its discussion of NTAP and ZEMDRI can be found online at: HIPPS.
Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced a strategic update and corporate restructuring to focus resources on the successful commercialization of ZEMDRITM in the United States, the Marketing Authorization Application (MAA) filing for ZEMDRI in the European Union, and continued development of the C-Scape program. Consistent with the Company’s mission, Achaogen’s research and development efforts will focus on C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, and new aminoglycoside antibiotics, both of which have non-dilutive funding commitments.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).
NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LXRX as the Company's latest news hit the wire. On May 04, 2018, the Company announced that new XERMELO® (telotristat ethyl) data from the randomized, double-blind, placebo-controlled Phase-3 TELESTAR study were published in March issue of Clinical Therapeutics. The publication provides the first report of the effects of XERMELO® on changes in weight in patients with neuroendocrine tumors (NETs) and carcinoid syndrome that participated in the Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome (TELESTAR) study.
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:30 AM Eastern Time. To listen ...